Highlights

  • SHANK2 mutation carriers showed significant differences across sensorimotor gating, startle habituation, and spontaneous sensorimotor behaviour versus matched community participants and unaffected siblings.
  • Sensory gating gap of approximately 54 percentage points between matched community participants and the SHANK2 group was statistically significant.
  • The study used the same core smartphone-based neurometric technology underlying BlinkLab Dx1, which is in its FDA 510(k) pivotal programme.
  • Results were completed ahead of the originally anticipated Q1 2027 readout, allowing early publication of the findings.
  • Further study readouts from BlinkLab's exploratory research programmes are expected before the end of calendar year 2026.

BlinkLab Limited (ASX:BB1), a neurotechnology company developing a smartphone-based diagnostic platform for autism, has reported findings from an exploratory study of SHANK2-related neurodevelopmental disorder. The study, conducted in collaboration with the SHANK2 Foundation, identified a multi-domain neurophysiological signature in individuals with SHANK2 mutations that was detected using the same core technology underlying BlinkLab Dx1 — the Company's most advanced product currently in its FDA 510(k) pivotal programme.

Latest Development

Twenty participants were recruited through the SHANK2 Foundation: nine individuals with a SHANK2 mutation and eleven unaffected siblings, of whom eight and ten respectively completed the 15-minute smartphone assessment. These were compared against a matched community group of 99 participants using the same experimental protocol. The study assessed acoustic startle response, prepulse inhibition, startle habituation, and spontaneous sensorimotor behaviour using computer vision analysis of the smartphone camera feed. Key findings include a statistically significant 54 percentage-point gap in sensory gating between the SHANK2 group (which showed negative gating of -26.5%) and both the matched community group (+27.2% gating) and siblings (+27.8% gating). Startle habituation and spontaneous sensorimotor behaviours also differed significantly between groups. The study was completed ahead of the previously anticipated Q1 2027 readout.

Company Background

BlinkLab was founded by neuroscientists at Princeton University and is developing a smartphone-based platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that uses smartphones, artificial intelligence, and Machine Learning to capture objective reflex-based neurometric measures. The FDA 510(k) pivotal programme for Dx1 is ongoing. The Company has established a Scientific Advisory Board with leading experts in autism and brain development, and operates multiple exploratory research programmes alongside the core Dx1 regulatory pathway.

Sector Context

Autism spectrum disorder is currently diagnosed primarily through specialist observation and interview-based assessments, which are time-consuming and subject to clinician variability. The absence of validated objective biomarkers has also limited the development of pharmacological treatments, as Clinical Trials lack reliable outcome measures beyond clinician-rated scales. The SHANK2 study is commercially significant not only for its diagnostic implications but also because rare genetically defined autism conditions provide biologically constrained models for identifying pathways relevant to broader autism heterogeneity. The connection between SHANK2 mutations and synaptic function also creates potential links to preclinical animal model research, which BlinkLab's founders have pursued at leading universities.

Market Perception

The identification of a consistent multi-domain neurophysiological and sensorimotor signature in a small but genetically defined cohort, using a standard smartphone assessment, adds biological credibility to the BlinkLab platform beyond its use in clinical autism diagnostics. For pharmaceutical companies developing targeted therapies for neurodevelopmental conditions, objective and scalable endpoint measures are a significant unmet need. The Company has explicitly referenced the potential for the platform to serve as a research tool and clinical trial endpoint in therapeutic development programs, which represents an addressable market beyond the diagnostic segment.

Growth Drivers

The SHANK2 study results open several commercial pathways for BlinkLab. First, positive results in a monogenic autism cohort strengthen the scientific case for the Dx1 platform to regulators and clinical customers ahead of its anticipated FDA clearance. Second, the platform's potential as a Drug Development tool — particularly for rare genetic neurodevelopmental conditions with preclinical model analogues — could attract pharmaceutical partnerships or research licensing arrangements. Third, the same core technology may be applicable across multiple biological subtypes, supporting future product extensions. Additional study readouts expected before year-end provide a near-term news flow catalyst.

Risks and Challenges

The SHANK2 study is exploratory in nature and uses a small cohort of eight affected individuals, which is inherent to rare genetic conditions. The statistical findings, while significant, are based on a cohort size where individual variation has an amplified impact. The study does not establish the diagnostic performance of Dx1 nor does it represent a clinical trial endpoint. The commercialisation pathway for the platform as a drug development tool is not established and requires significant further development work and partner engagement. The FDA 510(k) pivotal programme for Dx1 remains the Company's primary regulatory priority and is not affected by these exploratory findings.

Recent Announcements

The SHANK2 collaboration was announced in March 2026, and the study was included in a Company clinical update in July 2026 with an expected readout of Q1 2027. The earlier-than-anticipated completion allows BlinkLab to report these findings before year-end. This announcement was used to lift a Trading halt that the Company had entered on 9 November 2026.

Key Insights

BlinkLab has demonstrated that its smartphone-based neurometric technology can detect a biologically meaningful, multi-domain sensorimotor signature in a genetically defined autism cohort, adding scientific depth to the platform's potential applications. The consistent sensory gating, habituation, and spontaneous movement differences observed in SHANK2 mutation carriers — using the same core technology as the Dx1 diagnostic product — position BlinkLab as a potential platform company across autism diagnostics, patient stratification, and therapeutic development. Additional exploratory study readouts expected before year-end provide near-term milestones beyond the primary Dx1 FDA pivotal programme.